PhaseBio: PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60M
The company is being sued by the development partner for its lead new drug candidate.
Read full article »
PhaseBio is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases.
Read more